Azenta, Inc. Reports Strong Fiscal 2025 Year-End Results with Notable Growth

Azenta, Inc. Reports Fiscal 2025 Results

Azenta, Inc. (Nasdaq: AZTA), a leading player in the life sciences sector, announced its financial outcomes for both the fourth quarter and the full fiscal year 2025, concluding on September 30, 2025. The company experienced notable revenue growth as it adapts to evolving market demands, showcasing its strategic positioning and operational efficiencies.

Financial Overview

In the fourth quarter of fiscal 2025, Azenta reported a revenue of $159 million, marking a 6% increase year-over-year. From an organic standpoint, which strips out currency impact, the growth was 4%. For the entire fiscal year, total revenue rose to $594 million, a 4% growth compared to the previous year.

The company saw an impressive 11% revenue increase in its Multiomics segment and a steady 2% growth in Sample Management Solutions. The overall organic growth for the year was 3%.

Adjusted EBITDA and Margins

Azenta also highlighted significant margin improvements for the year. The Adjusted EBITDA margin rose by 310 basis points, showcasing the effectiveness of its cost management strategies. Specifically, the company's Adjusted EBITDA for the year reached $66 million, reflecting a 44% increase from the previous year’s results.

Management Insights

John Marotta, President and Chief Executive Officer of Azenta, commented on the fiscal year’s performance: “Fiscal 2025 was a transformative year for Azenta. We achieved core revenue growth and substantial margin expansion, indicating the success of our business strategies.” He further emphasized that the company enters fiscal 2026 in a stronger position, with a streamlined organizational structure focused on customer satisfaction.

Looking Ahead

For fiscal year 2026, Azenta anticipates organic revenue growth within the range of 3% to 5%, paired with an expected 300 basis points margin expansion. This forward-looking guidance reflects Azenta’s commitment to delivering sustained growth and maximizing shareholder value.

Conclusion

Azenta, Inc.'s fiscal 2025 results illustrate its successful navigation through the life sciences landscape. The strategic focus on improving core operations and enhancing customer-centric services indicates a bright trajectory as it approaches the next fiscal year. By maintaining an adaptive and forward-thinking approach, Azenta is positioning itself for even greater success in the future, aiming to bring advanced therapeutic solutions to market more efficiently.